Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Application of an artificial intelligence-based tool in [18F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma.
Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, John L, Weinhold N, Sauer S, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Among authors: goldschmidt h. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3697-3708. doi: 10.1007/s00259-023-06339-5. Epub 2023 Jul 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37493665 Free PMC article. Clinical Trial.
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, Leblay N, Maity R, Sankowski R, Lee H, Barakat E, Ahn S, Weinhold N, Rippe K, Bunse L, Platten M, Goldschmidt H, Müller-Tidow C, Raab MS, Bahlis NJ. Friedrich MJ, et al. Among authors: goldschmidt h. Cancer Cell. 2023 Apr 10;41(4):711-725.e6. doi: 10.1016/j.ccell.2023.02.008. Epub 2023 Mar 9. Cancer Cell. 2023. PMID: 36898378 Free article.
Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma.
Wennmann M, Grözinger M, Weru V, Hielscher T, Rotkopf LT, Bauer F, Gnirs R, Nonnenmacher T, Sauer S, Goldschmidt H, Weinhold N, Bonekamp D, Weber TF, Schlemmer HP, Delorme S. Wennmann M, et al. Among authors: goldschmidt h. Br J Radiol. 2023 Apr 1;96(1145):20220745. doi: 10.1259/bjr.20220745. Epub 2023 Apr 12. Br J Radiol. 2023. PMID: 37001052 Free PMC article.
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.
Wennmann M, Ming W, Bauer F, Chmelik J, Klein A, Uhlenbrock C, Grözinger M, Kahl KC, Nonnenmacher T, Debic M, Hielscher T, Thierjung H, Rotkopf LT, Stanczyk N, Sauer S, Jauch A, Götz M, Kurz FT, Schlamp K, Horger M, Afat S, Besemer B, Hoffmann M, Hoffend J, Kraemer D, Graeven U, Ringelstein A, Bonekamp D, Kleesiek J, Floca RO, Hillengass J, Mai EK, Weinhold N, Weber TF, Goldschmidt H, Schlemmer HP, Maier-Hein K, Delorme S, Neher P. Wennmann M, et al. Among authors: goldschmidt h. Invest Radiol. 2023 Oct 1;58(10):754-765. doi: 10.1097/RLI.0000000000000986. Epub 2023 May 22. Invest Radiol. 2023. PMID: 37222527
Reproducible Radiomics Features from Multi-MRI-Scanner Test-Retest-Study: Influence on Performance and Generalizability of Models.
Wennmann M, Rotkopf LT, Bauer F, Hielscher T, Kächele J, Mai EK, Weinhold N, Raab MS, Goldschmidt H, Weber TF, Schlemmer HP, Delorme S, Maier-Hein K, Neher P. Wennmann M, et al. Among authors: goldschmidt h. J Magn Reson Imaging. 2025 Feb;61(2):676-686. doi: 10.1002/jmri.29442. Epub 2024 May 11. J Magn Reson Imaging. 2025. PMID: 38733369 Free PMC article.
Detection of myeloma-associated osteolytic bone lesions with energy-integrating and photon-counting detector CT.
Grözinger M, Wennmann M, Sawall S, Wehrse E, Sedaghat S, Neelsen C, Bauer F, Goldschmidt H, Weru V, Ziener CH, Kopp-Schneider A, Schlemmer HP, Rotkopf LT. Grözinger M, et al. Among authors: goldschmidt h. Radiologie (Heidelb). 2024 Nov;64(Suppl 1):24-31. doi: 10.1007/s00117-024-01344-7. Epub 2024 Jul 17. Radiologie (Heidelb). 2024. PMID: 39020050 English.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
845 results